AI-powered discovery and translation of disease-driving cellular states from single-cell and spatial data.
From single-cell data to clinically actionable models
Scailyte combines large-scale single-cell and spatial omics data with longitudinal clinical outcomes to identify disease-driving cellular states. Our platform integrates multimodal data, advanced machine learning, and biological expertise to generate predictive and translatable models for diagnostics and therapeutics.
Proof of Value
From biological insight to clinical and commercial impact.
Partnering program
Optimizing NK Cell Therapy Manufacturing
The Insight
ScaiVision identified a previously unknown B-cell subpopulation in donor material that predicted manufacturing failure.
The Outcome
Solved a multi-million-dollar manufacturing bottleneck and was implemented as a QC marker.
Internal project
First-in-Class Tissue-Based Diagnostic
The Insight
Discovered unique molecular signatures in endometrial tissue that correlate with active lesions.
The Outcome
First-in-kind tissue-based molecular diagnostic with >90% specificity.
Commercialization
Asset successfully out-licensed to Hera Biotech for global commercialization.
internal project
High-Accuracy CTCL Blood-Based Diagnostic
The Insight
Discovered rare CTCL-specific CD4 T-cell populations for the clear differentiation of CTCL from Atopic Dermatitis.
The Outcome
Developed and validated an optimized 9-marker FACS-based diagnostic prototype with accuracy of 97%.
Commercialization
Validated and ready for licensing or strategic partnership. The asset includes a pending patent (EP19219889) and offers a rapid, cost-effective diagnostic solution.
